4D Molecular Therapeutics Inc. - notizie pubblicate 191 - letture 5.400
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
Announced positive interim data from prism phase 2 dose expansion cohort evaluating 4d-150 in wet amd patients with severe disease activity and high treatment burden enabling advan ...
4D MOLECULAR THERAPEUTICS INC.
Quarterly Report for Quarter Ending March 31, 2024 (Form 10-Q)
10-q united states securities and exchange commission washington, d.c. 20549 form 10-q (mark one) ☒ quarterly report pursuant to section 13 or 15(d) of the securities exchange ac ...
4D MOLECULAR THERAPEUTICS INC.
Results of Operations and Financial Condition - Form 8-K
4dmt reports first quarter 2024 financial results and operational highlights • announced positive interim data from prism phase 2 dose expansion cohort evaluating 4d-150 in wet a ...
4D MOLECULAR THERAPEUTICS INC.
4DMT to Participate in Upcoming Investor Conference
Emeryville, calif., may 07, 2024 (globe newswire) -- 4d molecular therapeutics (nasdaq: fdmt, 4dmt or the company), a leading clinical-stage genetic medicines company focused on un ...
4D MOLECULAR THERAPEUTICS INC.
Proxy Statement - Form DEF 14A
Table of contents united states securities and exchange commission washington, d.c. 20549 schedule 14a proxy statement pursuant to section 14(a) of the securities exchange act of 1 ...
4D MOLECULAR THERAPEUTICS INC.
Additional Proxy Soliciting Materials - Form DEFA14A
United states securities and exchange commission washington, d.c. 20549 schedule 14a proxy statement pursuant to section 14(a) of the securities exchange act of 1934 filed by the r ...
4D MOLECULAR THERAPEUTICS INC.
Annual Report - Form ARS
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer 4d molecular therapeutics inc. publish ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
Conducted initial pivotal study interactions with the u.s. food and drug administration (fda) and european medicines agency (ema); company has clear registration path for 4d-710 fo ...
4D MOLECULAR THERAPEUTICS INC.
4DMT to Participate in Upcoming Investor Conferences
Emeryville, calif., march 04, 2024 (globe newswire) -- 4d molecular therapeutics (nasdaq: fdmt, 4dmt or the company), a leading clinical-stage genetic medicines company focused on ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
Presented positive interim data from randomized dose expansion cohort of the phase 2 prism study evaluating 4d-150 in wet amd patients with severe disease activity and high treatme ...
4D MOLECULAR THERAPEUTICS INC.
Sales Agreement - Form 8-K
4dmt reports full year 2023 financial results and operational highlights • presented positive interim data from randomized dose expansion cohort of the phase 2 prism study evalua ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti